$0.238
-0.010 (-4.35%)Al cierre
Noticias de NNOX
Eventos de NNOX
Company Expects Cash to Drop to $26 Million by 2026
On a preliminary unaudited basis, the company expects its cash, cash equivalents, short-term deposits and long-term restricted deposits to be approximately $26.0 million as of September 30, 2026, as compared to $60.0 million as of December 31, 2025. The company expects to continue to incur significant costs related to its ongoing operations. Management expects that the company's cash and cash equivalents, and deposits, as of September 30, 2026, are not sufficient to support the company's operations under its current operating plans for at least one year from the date of this press release. These factors raise substantial doubt as to the company's ability to continue as a going concern. If the company is unable to raise additional funds when needed, it may be required to delay, reduce or eliminate its product development or future commercialization efforts, or grant rights to develop and market products that it would otherwise prefer to develop and market itself.
Nanox AI Enters Distribution Agreement with Tecnologie Avanzate
Nanox AI entered into a distribution agreement with Technologic s.r.l., an affiliate of Tecnologie Avanzate, to commercialize Nanox.AI's Bone Solution in Italy. The collaboration leverages Tecnologie Avanzate's experience, established healthcare industry relationships, and expertise in the Italian market.
Company Expects Q3 Revenue of Approximately $4.3 to $4.4 Million
On a preliminary unaudited basis, the company expects its revenue to be approximately $4.3 to $4.4 million for the three months ended September 30, compared to $3.4 million for the corresponding three-month period in 2025. During the Reported Period, the Company generated revenue through teleradiology services, the sale and deployment of its imaging systems and its AI and software solutions. The company's revenue from teleradiology services for the Reported Period was approximately $3.1 million, compared to revenue of $3.1 million in the Comparable Period. During the Reported Period, the Company generated revenue through the sale and deployment of its imaging systems and OEM services which amounted to approximately $0.3 million for the Reported Period, compared to revenue of $0.2 million in the Comparable Period. This increase in revenue is related mainly to an additional Nanox.ARC CapEx agreement. The company's revenue from its AI and software solutions for the Reported Period was $1.0 million, compared to revenue of $0.1 million in the Comparable Period. This increase in revenue is related mainly to the consolidation of Vaso Healthcare IT by the company.
Nanox Reports Q2 Revenue of $4.16M, Below Consensus
Reports Q2 revenue $4.16M, consensus $5.39M. "To date there has been tangible progress in our commercialization strategy. We have expanded our U.S. distribution footprint to ten partners and begun patient scanning at our first Nanox Imaging Network site in Philadelphia. We have begun receiving reimbursement for scans from insurers for our NIN business. At the same time, Nanox.AI is gaining commercial traction from our new agreement with Vertec Scientific in the UK. In addition, we are advancing our efforts to pursue a potential new CMS reimbursement pathway that could support broader adoption," said Erez Meltzer, acting chairman and CEO. "We have also implemented a multi-pronged cost reduction initiative that includes the restructuring of our South Korea operations, and have raised additional capital to support our operations. We remain focused on disciplined execution as we move systems from our sales pipeline into active clinical use."
Stock Futures Rise as Micron's Strong Earnings Boost Market Sentiment
Stock futures are higher this morning as technology stocks attempt to regain leadership after several volatile sessions. Investors had started questioning whether the AI trade was losing momentum, but the latest chip demand signals are pushing the narrative back toward continued infrastructure expansion.Micron reported strong results and disclosed roughly $22B in forward chip commitments, lifting sentiment across the broader chip complex. The move is helping ease concerns that recent weakness in AI-related stocks represented a deeper shift in demand. The question now is whether this becomes a durable restart for the AI trade or simply a relief rally after a sharp pullback.In pre-market trading, S&P 500 futures rose 0.76%, Nasdaq futures rose 2.29% and Dow futures rose 0.24%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -IBMup 2% after unveiling the world's first sub-1 nanometer chip technologyUP AFTER EARNINGS -Micronup 19%TD Synnexup 8%Acuityup 7%BlackBerryup 7%McCormickup 3%Commercial Metalsup 1%DOWN AFTER EARNINGS -Nano-X Imagingdown 13%Dardendown 3%Winnebagodown 3%
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.